Data Updates in the Treatment of Resectable Cutaneous Squamous Cell Carcinoma (CSCC) - Episode 9

Lessons Learned in Other Cancers and Suggested Endpoints in Future Trials

, , ,

Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.

EP. 1: Cutaneous Squamous Cell Carcinoma: Incidence and Risk Factors
EP. 2: Available Staging Systems for Cutaneous Squamous Cell Carcinoma
EP. 3: Optimal Risk Stratification in Patients With Cutaneous Squamous Cell Carcinoma
EP. 4: Defining Resectability in CSCC
EP. 5: Staging and Risk Stratification’s Impact on Treatment Approach in CSCC
EP. 6: Real World Experience With Resectable Cutaneous Squamous Cell Carcinoma
EP. 7: Evolving Treatment Paradigm of Resectable CSCC
EP. 8: Clinical Experience With Neoadjuvant IO Therapy in Melanoma
Now Viewing
EP. 9: Lessons Learned in Other Cancers and Suggested Endpoints in Future Trials
EP. 10: Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates
EP. 11: CSCC: Translating Cemiplimab Data Into Practice
EP. 12: Other Emerging Treatment Modalities in Cutaneous Squamous Cell Carcinoma
EP. 13: Best Practices in Multidisciplinary Care for CSCC
EP. 14: CSCC: Escalating Therapy for High-risk Patients
EP. 15: Practical Advice on the Evolving Management of CSCC